Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)

12.69
Delayed Data
As of Aug 28
 +0.56 / +4.62%
Today’s Change
5.60
Today|||52-Week Range
13.88
+99.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.3B

Company Description

Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease. The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. The company uses its proprietary gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications. Lexicon Pharmaceuticals was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Contact Information

Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands Texas 77381-1160
P:(281) 863-3000
Investor Relations:

Employees

Shareholders

Other institutional70.88%
Mutual fund holders23.68%
Individual stakeholders--

Top Executives

Lonnel CoatsPresident, Chief Executive Officer & Director
John NorthcottVP-Marketing, Commercial Strategy & Operations
Jeffrey L. WadeCFO & EVP-Corporate & Administrative Affairs
Pablo LapuertaChief Medical Officer & EVP-Clinical Development
Brian T. CrumSecretary, Vice President & General Counsel